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a  b  s  t  r  a  c  t
Ethnopharmacological  relevance:  Vernonia  scorpioides  (Asteraceae)  is  a native  Brazilian  medicinal  plant
that  is  commonly  used  to  treat  skin  disorders.  Considering  the  traditional  use  of  Vernonia  scorpioides
and  the  lack  of  information  about  its pharmacological  properties,  we  investigated  the  topical  anti-
inﬂammatory  effect  of  the  ethanolic  extract  of  Vernonia  scorpioides  (EEVS)  on acute  and  chronic  cutaneous
inﬂammation  models  in  mouse.
Materials  and  methods:  The  topical  anti-inﬂammatory  effect  of EEVS  was  evaluated  against  acute  models
(12-O-tetradecanoylphorbol  acetate  (TPA)-  and  arachidonic  acid  (AA)-induced  mouse  ear  oedema)  and
chronic  models  (multiple  applications  of  croton  oil).
Results:  The  EEVS  caused  a dose-related  inhibition  of  oedema  in  both  the  TPA-  and  AA-induced  acute  mod-
els (DI50 =  0.24  and  0.68  mg/ear  with  an  inhibition  of 80 ±  5%  and  65 ± 5%,  respectively,  for  1 mg/ear).  In
addition,  the  TPA-induced  increase  in  myeloperoxidase  activity  (MPO)  in the  ear was  reduced  (77  ±  8%)
by the  topical  application  of  EEVS.  In  the  chronic  model,  the  EEVS  reduced  all parameters  evaluated:
oedema  formation  (31  ±  2%),  epidermal  hyperproliferation  (histology)  and  MPO (25 ± 10%).  However,
the  topical  treatment  of  EEVS  had no  effect  on  N-acetyl--d-glucosaminidase  activity.  The  EEVS effec-
tively  interfered  in  the  ear  oedema  on  the  delayed-type  hypersensitivity  reaction  induced  by  oxazolone.
The  topical  treatment  with  EEVS  performed  on  both  phases  or  only  on  the  elicitation  phase  caused  the
inhibition  of  the ear  oedema-induced  by  oxazolone  in  42.9%  and  63.4%,  respectively,  when  compared  to
control  animals  (sensitized  and  challenged).
Conclusions:  The  results  suggest  that  EEVS  is  effective  as  a topical  anti-inﬂammatory  agent  in acute  and
chronic  inﬂammatory  processes  and  that  its  action  is  markedly  inﬂuenced  by  the  inhibition  of  neutrophil
migration  into  inﬂamed  tissue  as  well  as  by epidermal  hyperproliferation.
 . Introduction
Medicinal plants are widely used to treat skin disorders. The
fﬁcacy of certain plants, such as Matricaria recutita, Hamamelis
irginiana, Arnica montana and Calendula ofﬁcinalis has been estab-
ished by pre-clinical and clinical studies (Bedi and Shenefelt, 2002).
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Several species of genus Vernonia (Asteraceae) are used in tradi-
tional medicine to treat various ailments (Johri and Singh, 1997).
Recent studies focusing on the anti-inﬂammatory (Mazumder et al.,
2003), anti-pyretic (Gupta et al., 2003), anti-cancer (Izevbigie et al.,
2004) and anti-malarial activities of several Vernonia species have
been published. Vernonia scorpioides (Lam.) Pers. is a Brazilian herb
that grows in poor and deforested soils all over the country (Leite
et al., 2002), and it is used topically by native people to treat a
variety of skin conditions, such as allergies, skin parasites, irrita-
Open access under the Elsevier OA license.tions, skin injuries, itching and chronic wounds, including ulcers
of the lower limbs (Pagno et al., 2006). Pharmacological studies of
Vernonia scorpioides indicated the fungicidal activity of the plant’s
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t al., 1996); mild wound healing effects for its ethanolic extract
Leite et al., 2002) and antitumoural activity for its dichloromethane
raction (Pagno et al., 2006).
Members of the genus Vernonia are sources of sesquiterpene
actones, typical constituents of the Asteraceae family, which
ave been identiﬁed as the active compounds in a variety of
edicinal plants used in traditional medicine for the treatment
f inﬂammatory diseases (Valério et al., 2003). In addition, phyto-
hemical studies have reported the presence of compounds, such
s ﬂavonoids, steroids and polysaccharides, which contribute to
he anti-inﬂammatory and immunomodulating activity of some
edicinal plants from the genus Vernonia (Huang et al., 2003;
chinda et al., 2003; Nergard et al., 2004). These compounds may
ct in several inﬂammatory pathways or interact with mediators
nvolved in the inﬂammatory response, such as arachidonic acid
etabolites, cytokines, nitric oxide, cyclooxigenase-2, phospholi-
ase A2, nuclear factor-B and others (Calixto et al., 2003), making
he plants of Asteraceae family promising as a new therapy for
nﬂammatory skin conditions.
Skin is well-known for its functional role as a protective phys-
cal barrier. It is now clear that skin is far more than a mere
ontainer but rather is a dynamic organ that has other recog-
ised functions, such as endogenous homeostasis, metabolism and
ensory input. In addition, skin actively participates in immunolog-
cal regulatory processes and inﬂammatory responses (Bos, 1997).
owever, some inﬂammatory or immunological reactions lead to
hronic inﬂammation processes, such as psoriasis or to intolerable
kin inﬂammation conditions, such as contact dermatitis, which
equires medication (Robert and Kupper, 1999).
Considering the traditional use of Vernonia scorpioides on skin
isorders and that no information is available about its topical
nti-inﬂammatory properties, we investigated the topical anti-
nﬂammatory effect of the ethanolic extract of Vernonia scorpioides
EEVS) on acute and chronic cutaneous inﬂammation models in
ice.
. Materials and methods
.1. Plant material
Aerial components (leaves and ﬂowers) of Vernonia scorpioides
Lam.) Pers. (Asteraceae) were collected in November 2005 from
ild specimens in a “restinga” forest (a distinct type of coastal
ropical and subtropical moist broadleaf forest) in Navegantes (SC),
nd the identity of the specimens was conﬁrmed by Dr Ana Clau-
ia Araújo (Universidade do Vale do Itajaí, Santa Catarina, Brazil).
oucher specimens [M.  Biavatti 11 (15/03/01)] were deposited at
he Herbário Barbosa Rodrigues (Itajaí, Santa Catarina, Brazil).
.2. Chemicals
For this study, 12-O-tetradecanoylphorbol acetate (TPA),
9% arachidonic acid (AA), croton oil, 4-ethoxymethylene-2-
henyl-2-oxazolin-5-one (oxazolone), dexamethasone acetate,
ndomethacin, sodium phosphate-buffered saline (PBS), hexade-
yltrimethylamonium bromide (HTAB), tetramethylbenzidine HCl
TMB), N,N-dimethylformamide (DMF), p-nitrophenyl-acetamide-
-d-glucopyranoside, glycine and foetal bovine serum (FBS) were
btained from Sigma–Aldrich Co. (St. Louis, USA). Anti-mouse
D45/FICT was purchased from BD Biosciences Pharmingen (San
iego, USA), and acetone, absolute ethanol, dimethylformamide,ormaldehyde, acetic acid, sodium citrate and sodium acetate were
btained from Merck Biosciences (Bad Soden, Germany). Hydro-
en peroxide (H2O2), eosin, hematoxyline, ﬂoxine B and xylol were
urchased from Vetec (Rio de Janeiro, Brazil).macology 138 (2011) 390– 397 391
2.3. Preparation of extract
The fresh leaves and ﬂowers of the plant (3 kg) were crushed
with bidistilled ethanol (6 L) in a domestic mixer and macerated
for 7 days in the absence of light, and the extract obtained was
ﬁltered and dried under vacuum using a Rotary Vacuum Evapora-
tor (Quimis, São Paulo, Brazil), resulting in 37 g of a crude extract
(1.2%, w/w),  named ethanol extract of Vernonia scorpioides (EEVS).
An aliquot of the crude extract obtained was used to perform the
pharmacological assays; each aliquot was  properly diluted in ace-
tone (20 L) to reach the selected dose.
2.4. Pharmacological assays
2.4.1. Animals
Experiments were performed using groups of 5 male Swiss
mice (20–30 g) that were kept at a controlled room temperature
(22 ± 1 ◦C) and under a 12 h light/dark cycle (lights on at 07:00 h)
with water and food given ad libitum. Experiments were performed
in accordance with guidelines speciﬁed by the Ethics Commit-
tee on Animal Experimentation, and the experimental protocol
was  approved by the Institution Ethics Committee for Animal Use
(protocol number 127, UFPR) in accordance with international
guidelines.
2.4.2. TPA-induced mouse ear oedema
TPA-induced ear swelling in mice was  performed according to
the method described by Young et al. (1983).  Ear oedema was
induced on the right ear by topical application of 2.5 g/ear of
TPA dissolved in 20 L acetone. Both EEVS (0.003–1 mg/ear) and
dexamethasone (0.05 mg/ear), which was  used as positive control,
were also dissolved in 20 L of acetone and were applied after the
TPA. Ear thickness was  measured before and 6 h after induction of
inﬂammation using a digital micrometer (MT-045B, Shangai Metal
Great Tools Co., Ltd., Shangai, China). Oedema was expressed as the
difference between the basal ear thickness and the ear thickness
after 6 h of TPA application. Animals were euthanised 24 h after
TPA treatment, and tissue samples (6 mm)  were removed from the
animals’ right ears and stored at −70 ◦C until use in the myeloper-
oxidase assay (MPO).
2.4.3. Multiple croton oil application-induced mouse ear oedema
Croton oil is a relatively crude mixture of many constituents,
including phorbol esters, which elicit skin inﬂammation and hyper-
proliferative responses in animals. Chronic inﬂammation was
induced by the application of 0.4 mg/ear of croton oil dissolved in
20 L of acetone on alternated days for 9 days (Stanley et al., 1991).
EEVS was topically applied (1 mg/ear) twice a day during the last
4 days of the experiment. Dexamethasone was used as the refer-
ence drug (0.05 mg/ear). Oedema was expressed as the change in
ear thickness due to croton oil application, and ear thickness was
measured every day over the 9-day experiment. The animals were
euthanised on day 9, and ear samples (6 mm)  were removed and
stored at −70 ◦C for use in the following assays.
2.4.4. Tissue MPO assay
MPO  is an enzyme present in the intracellular granules of
neutrophils, and it can be used as a marker for the inﬂux of poly-
morphonuclear leucocytes into inﬂamed tissues. MPO activity was
evaluated according to the method proposed by Bradley et al.
(1982) and modiﬁed by De Young et al. (1989).  Mice were sacriﬁced
24 h after a single TPA application and 6 h after the last applica-
tion of croton oil on day 9. Each ear sample (6 mm)  was placed in
0.75 ml  of 80 mM sodium phosphate buffer (PBS, pH 5.4) containing
0.5% hexadecyltrimethylamonium bromide (HTAB). Next, the sam-


























































a markedly increased leucocyte count in the control group com-92 L.K. Rauh et al. / Journal of Ethn
omogenate was decanted into a microfuge tube, and the washes
rom a second 0.75 ml  aliquot of HTAB in PBS were added to the
ube. The 1.5 ml  mixture was centrifuged at 11,200 × g at 4 ◦C for
0 min. The supernatant samples (triplicates of 30 L) were added
o 96-well microtitre plates. For the assay, 200 L of a mixture con-
aining 100 L of 80 mM PBS (pH 5.4), 85 L of 0.22 M PBS (pH 5.4)
nd 15 L of 0.017% H2O2 were added to the wells. The reaction
as started by the addition of 20 l of 18.4 mM tetramethylbenzi-
ine HCl (TMB) in dimethylformamide. The mixture was  incubated
or 3 min  at 37 ◦C, and the reaction was subsequently stopped by
he addition of 30 L of 1.46 M sodium acetate (NaOAc, pH 3.0).
nzyme activity was determined colourimetrically using a plate
eader (EL808B, BioTech Instruments, INC, Winooski, VT, USA) to
easure absorbance at 620 nm,  and the results were expressed as
DO  per biopsy.
.4.5. Tissue N-acetyl-ˇ-d-glucosaminidase (NAG) assay
According to the method used by Sanchez and Moreno (1999),
ar samples (6 mm)  were treated using the same method described
or the MPO  assay. The supernatant samples (triplicates of 25 L)
ere added into 96-well microtitre plates. For the assay, 25 L
f p-nitrophenyl-acetamide--d-glucopyranoside (2.24 mM)  and
00 L of 50 mM buffer citrate (pH 4.5) per well were used. The
ixture was incubated for 60 min  at 37 ◦C, and the reaction was
topped by the addition of 100 L of 200 nM buffer glycine (pH
0.4). The enzyme activity was determined colourimetrically using
 plate reader (EL808B, BioTech Instruments, INC, Winooski, VT,
SA) to measure absorbance at 405 nm,  and enzyme activity was
xpressed as mDO  per biopsy.
.4.6. Flow cytometric analysis of cell surface marker (CD45) on
eucocyte population
Ear tissue samples were placed in 1 ml  of 80 mM  sodium phos-
hate buffer (PBS, pH 5.4), homogenised in low temperature in a
otor-driven homogeniser and ﬁltered with a ﬁlcon ﬁlter (100 m
ore size). Pooled cells (106) were incubated with an antibody spe-
iﬁc against anti-CD45/FICT, a common leucocyte marker, in PBS/1%
BS for 30 min  and washed three times with PBS. Ten thousand
ells per sample were analysed by CellQuest software (BD, Franklin
akes, USA) in a FACSCalibur (BD, Franklin Lakes, USA) ﬂow cytome-
er, and the experiments were analysed using WinMDI 2.9 software
Miscellaneous software, The Scripps Research Institute, CA, USA).
.4.7. Histology
Ear samples were ﬁxed in ALFAC (formaldehyde, ethanol 80%,
lacial acetic acid) solution. Each sample was cut longitudinally
nto equal halves. Half of each sample was embedded in parafﬁn,
ut into 5 m sections and stained with hematoxylin–eosin. A
epresentative area was selected for qualitative light microscopic
nalysis of the inﬂammatory cellular response at magniﬁcations
f 200× and 400×.
.4.8. Arachidonic acid (AA)-induced mouse ear oedema
AA-induced ear oedema in mice was achieved according to
he method used by Young et al. (1984).  AA (2 mg)  was  dissolved
n 20 L of acetone and applied to the right ear of the animals.
EVS (0.03–1 mg/ear) and indomethacin (2 mg/ear, reference drug)
ere applied topically after the application of AA (2 mg/ear). Ear
hickness was measured before and 1 h after induction of oedema.
edema was measured as indicated above and expressed as an
ncrease in the ear thickness due to AA application..4.9. Oxazolone induced contact-delayed-type hypersensitivity
DTH)
Oxazolone-induced dermatitis induction was achieved accord-
ng to the previously published method used by Fujii et al. (2002).macology 138 (2011) 390– 397
To  induce DTH, mice were sensitized by the application of 2%
oxazolone in acetone (50 L) on the shaved abdomen skin for
two consecutive days, and this treatment was  followed by the
application of EEVS (1 mg/site, 50 L) or the reference drug dex-
amethasone (0.05 mg/site, 50 L) on the same region. After 6 days,
the challenge was performed by the application of 30 L of 2% oxa-
zolone in acetone on both sides of the mouse ear (elicitation phase).
EEVS (1 mg/ear) and dexamethasone (0.05 mg/ear) were topically
applied (30 L) 1, 24, 36, 48, 60, 72, 84 and 96 h after the challenge
with oxazolone, and the ear thickness was  measured each 24 h for
4 days using a digital micrometer as described above.
2.5. Statistical analysis
Results are presented as means ± S.E.M. except the ID50 values
(i.e., the dose of EEVS that reduces the inﬂammatory response by
50%, relative to the control), which are reported as geometric means
accompanied by their respective 95% conﬁdence limits. Data were
subjected to analysis of variance (ANOVA) followed by a post hoc
Newman–Keuls test. The accepted level of signiﬁcance for the test
was  P < 0.05. The ID50 values were determined by linear regression
from individual experiments using the GraphPad Software (Prism
version 3.0, San Diego, CA, USA).
3. Results
3.1. Effect of EEVS on TPA-induced mouse ear oedema and tissue
MPO  assay
Topical application of the vehicle (acetone) did not alter the ear
thicknesses of the mice (data not shown), but the application of
TPA promoted an increase in ear thickness. However, the applica-
tion of EEVS caused signiﬁcant and dose-dependent inhibition of
the TPA-induced skin oedema. Calculated mean ID50 value for this
EEVS inhibition was 0.24 (0.1–0.55) mg/ear with a maximal inhibi-
tion of 80 ± 5% (1 mg/ear). Topical application of EEVS also reduced
the MPO  activity with a maximum effect of 77 ± 8% (1 mg/ear). The
reference drug dexamethasone (0.05 mg/ear) also caused a signiﬁ-
cant inhibition of 88 ± 1% and 80 ± 3%, respectively, for oedema and
MPO  activity (Fig. 1).
3.2. Effect of EEVS on the croton oil multiple application-induced
mouse ear oedema and cellular inﬁltration
When tested after the establishment of skin inﬂammation, the
chronic treatment with EEVS (1 mg/ear, 2× per day, 4 days) and
dexamethasone (0.05 mg/ear, 2× per day, 4 days) promoted a sig-
niﬁcant inhibition of the oedema induced by croton oil on day
9 (31 ± 2% and 30 ± 9%, respectively) (Fig. 2A). Repeated treat-
ment of EEVS also caused a moderate inhibition of MPO  activity
(25 ± 10%) compared to the standard substance dexamethasone
(57 ± 8%) (Fig. 2C). As shown in Fig. 2B, the NAG activity was  not
modiﬁed by EEVS treatment; however, the activity of this enzyme
was  inhibited by dexamethasone treatment, undergoing a reduc-
tion to 25 ± 7% (Fig. 2B).
3.3. Flow cytometric analysis of leucocyte inﬁltration in the
croton oil multiple applications model
EEVS’s control over the cellular inﬁltration in a chronic inﬂam-
matory process was conﬁrmed by the quantiﬁcation of total
leucocytes in the inﬂamed tissue. Flow cytometric analysis revealedpared to the vehicle group (36% vs 2.6%) as shown in Fig. 3A and
B, respectively. This analysis also showed a reduction of leucocyte
numbers in groups treated topically with EEVS and dexamethasone
(27% and 23%, respectively).
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Fig. 1. Topical effect of ethanolic extract of Vernonia scorpioides (EEVS) and dexam-
ethasone (Dexa) on TPA-induced ear oedema (A) and MPO  activity on TPA-treated
ears (B). Ear oedema and MPO  activity were measured at 6 and 24 h after TPA
treatment, respectively. The control group only received acetone topically after the





















Fig. 2. Topical effect of Vernonia scorpioides ethanolic extract (EEVS) on the croton
oil  multiple application-induced mouse ear oedema. The chronic inﬂammation pro-
cess was induced by multiple applications of croton oil (0.4 mg/ear) in alternated
days during 9 days. The EEVS (1 mg/ear) and dexamethasone (0.05 mg/ear) were
applied topically during the last 4 days (2× per day) of the experiment (indicated
by the arrow), and the ear thickness was measured daily (A). In the last day of the
experiment, tissue samples from the ears were collected to evaluate NAG (B) and
MPO  activity (C). The vehicle group (V) received only acetone. The bars representepresent the mean ± S.E.M. for 5–6 animals. The asterisks denote the signiﬁcance
evels when compared with control groups. Signiﬁcantly different from control (C),
**p  < 0.001.
.4. Histological analysis
Repeated treatment with the vehicle showed no alterations
n cutaneous morphology in the histological analysis (Fig. 4A).
ultiple applications of croton oil induced an intense increase
n the ear diameter (oedema formation), epidermal hyperpro-
iferation (acanthosis) and leucocyte inﬁltration into the dermis
Fig. 4B). The EEVS treatment as well as the positive control
examethasone (0.05 mg/ear) markedly reduced the keratinocyte
yperproliferation caused by repeated croton oil application,
hereby reducing acanthosis formation. Similar treatments of EEVS
1 mg/ear) or dexamethasone also suppressed other inﬂammatory
arameters, such as oedema formation and leucocyte inﬁltration
Fig. 4).
.5. Effect of the ethanolic extract on the AA-induced mouse ear
edemaTopical application of AA on the right ear produced signiﬁ-
ant oedema formation peaking at 1 h after challenge. The EEVS
pplication exhibited a signiﬁcant and dose-dependent inhibi-
ion of the AA-ear oedema formation. The estimated mean ID50the mean ± S.E.M. for 5–6 animals. The asterisks denote the signiﬁcance levels when
compared with control groups. Signiﬁcantly different from control (C), *p < 0.05,
**p < 0.01, and ***p < 0,001.
for EEVS derived from the oedema inhibition study was 0.68
(0.41–1.13) mg/ear with a maximal inhibition of 60 ± 8% (1 mg/ear).
Similarly, the reference drug indomethacin (2 mg/ear) also caused
a signiﬁcant inhibition of AA-induced ear oedema, showing a max-
imal inhibition of 65 ± 5%. The results obtained are shown in
Fig. 5.
394 L.K. Rauh et al. / Journal of Ethnopharmacology 138 (2011) 390– 397

















aday  9) and homogenised. Pool of the ears (10−6 cells/group, n = 5) were processed a
howed that 2.6%, 36%, 27% and 23% among of cell types represents leukocytes in t
r  dexamethasone (0.05 mg/ear) (D), respectively.
.6. Effect of EEVS on oxazolone-induced contact-delayed-type
ypersensitivity
Sensitisation with oxazolone elicited a marked increase in ear
edema that persisted until 96 h after the challenge; however,
his effect was not observed in the non-sensitized group. Ear
edema was potently suppressed by EEVS (1 mg/ear), even in the
rst 24 h after challenge, showing an inhibition of 42 ± 9% with
his effect lasting until 96 h. The positive control dexamethasone
0.05 mg/site) showed a similar effect (Fig. 6A). Unexpectedly,
reatment with EEVS and dexamethasone at the same doses during
he sensitisation phase alone was unable to avert the oedema
ig. 4. Histological analysis of Vernonia scorpioides ethanolic extract effect on the croton
ollected in the last day of experiment (day 9) and stained with hematoxylin–eosin (inc
roton oil (B), croton oil plus EEVS (1 mg/ear) (C) and croton oil plus dexamethasone (0
nimals for each treatment were taken.ubated with an anti-CD45/FICT and acquired by ﬂow cytometer. The pool analysed
icle group (A), control group (B), group topically treated with EEVS (1 mg/ear) (C)
formation when the animals were re-exposed to oxazolone
(Fig. 6B). Treatment with these agents in the elicitation phase
(challenge) alone was  able to inhibit ear oedema formation,
reproducing the results obtained when the animals were treated
on both phases of oxazolone exposition (Fig. 6C).
4. Discussion and conclusionFor the ﬁrst time, we demonstrate the topical anti-inﬂammatory
activity of the EEVS in acute and chronic skin inﬂammation. The
phlogistic agents used in our experiments have long been accepted
 oil multiple applications. Representative pictures of transversal slices from ears
rease of 200× and 400×, scale 100 m).  Ears without treatment (A), treated with
.05 mg/ear) (D). Five slices from each animal were analysed and a minimum of 3
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Fig. 5. Topical effect of Vernonia scorpioides ethanolic extract (EEVS) on AA-induced
ear oedema. AA was administered topically (2 mg/ear) and immediately after EEVS













































Fig. 6. Topical effect of Vernonia scorpioides ethanolic extract (EEVS) on the oxa-
zolone induced contact-delayed-type hypersensitivity. The animals were sensitized
and after 6 days they were re-exposed to oxazolone. The topical treatment with EEVS
(1  mg/site) and dexamethasone (0.05 mg/site) was carried out on both phases (A),
in  the sensitization phase (B) and in the elicitation phase (C). A group of animals
was  treated just with vehicle (control) and another group was not previously sensi-m)  1 h after. The bars represent the mean ± S.E.M. for 5–6 animals. The asterisks
enote the signiﬁcance levels when compared with control groups. Signiﬁcantly
ifferent from control (C), **p < 0.01; ***p < 0.001.
s useful pharmacological tools for the investigation of new anti-
nﬂammatory drugs, allowing the identiﬁcation of potential drugs,
ncluding substances of plant origin and plant extracts (Gábor,
000), to treat inﬂammatory skin disorders. TPA is one of the phor-
ol ester constituents of croton oil (Gábor, 2000), and its topical
pplication triggered local inﬂammation with oedema formation,
olymorphonuclear leucocytes inﬁltration and epidermal hyper-
roliferation as consequence of the production of inﬂammatory
ediators, such as prostaglandin E2, leucotrienes, histamine, sero-
onin and IL-1 (Furstenberger et al., 1994). Corticoid-like agents,
hospholipase A2 and cyclooxygenase inhibitors as well as 5-
ipoxigenase inhibitors and LTB4 antagonists are highly effective
gainst the inﬂammation caused by TPA (Furstenberger et al., 1994;
ábor, 2000). With an extent of activity comparable to that of
he standard drug dexamethasone, EEVS inhibited two important
vents related to the skin inﬂammatory response induced by a
ingle application of TPA and multiple applications of croton oil:
edema formation and the migration of neutrophils, as determined
y MPO  activity assays and ﬂow cytometry. Neutrophil activation
esults in increases in the leucotrienes and prostaglandins released
n the skin, and the obstruction of the synthesis of these inﬂam-
atory mediators could explain the anti-inﬂammatory activity of
ertain plants used in the treatment of skin disorders (Bradley
t al., 1982). In addition, compounds that inhibit neutrophil inﬁltra-
ion can also reduce oedema formation and eicosanoid production
t the inﬂamed site (Sanchez and Moreno, 1999). According to
ur results regarding oedema and cell inﬁltration, the topical
nti-inﬂammatory properties of Vernonia scorpioides proves to be
nteresting because the accumulation of neutrophils in the skin
lays a critical role in cutaneous inﬂammatory diseases, such as
ermatitis and psoriasis.
The inhibition of inﬂammatory oedema and leucocyte migration
o ear skin challenged with TPA by different sesquiterpene lactones
as demonstrated by Recio et al. (2000).  Sesquiterpenes lactones,
uch as hirsutinolides and glaucolides, are commonly found in Ver-
onia species (Jakupovic et al., 1985; Kuo et al., 2003). Regarding
he chemical composition of the EEVS, it has been exhaustively
tudied and the main compounds found were: the known triter-
enes lupeol and lupeol acetate together with the widespread
teroids -sitosterol and stigmasterol, the sesquiterpene lactones
glaucolides and hirsutinolides) such as diacethylpiptocarphol
nd related hirsutinolides, ﬂavonoids (luteolin and apigenin)tized with oxazolone (no-sensitized). The bars represent the mean ± S.E.M. for 5–6
animals. The asterisks denote the signiﬁcance levels when compared with control
groups. Signiﬁcantly different from control (C), *p < 0.05, **p < 0.01, and ***p  < 0.001.
and cinnamic acid derivatives (caffeic acid and ethyl caffeate)
(Buskuhl et al., 2010), and also a polyacetylene (Buskuhl et al.,
2009).
The general action mechanism of sesquiterpene lactones involve
the transcription factor NF-B throughout the alkylation of the
p65 subunit cysteine residue of the NF-B complex (Buskuhl et al.,
2009) or the inhibition of NF-B activation by preventing the degra-
dation of IB. Both cases inhibited the interaction of NF-B with
DNA (Valério et al., 2003), thereby resulting in a reduction in the
synthesis of inﬂammatory mediators, such as chemotatic cytokines.
Certain hirsutinolides isolated from Vernonia triﬂosculosa inhibited
IL-8 production in in vitro studies (Kos et al., 2006). Given that IL-8
exerts a potent chemotatic action, the effect of EEVS on neutrophil
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s consequence of the presence of sesquiterpene lactone. However,
EVS did not exert any action over the inﬁltration of mononu-
lear phagocytes, which represent the main cell type involved in
he chronic inﬂammation. However, the reduction of neutrophil
nﬁltration in the dermis can promote a relative inﬂammatory reso-
ution because neutrophils collaborate in the release of free radicals,
nﬂammatory mediators and proteolytic enzymes (Bradley et al.,
982).
One critical action of EEVS was the reduction of acanthosis inci-
ence, which is an indicator of the hyperproliferation of epidermis
eratinocytes. The repeated application of croton oil increases the
evels of IL-1 and TNF- as well as COX-2 expression (Stanley et al.,
991). The suppression of these cytokines and of prostaglandin E2
roduction could be the mechanism through which EEVS abolishes
he epidermal hyperproliferation, oedema formation and leucocyte
nﬁltration. Again, the expression of these cytokines and COX-2
s well as the actions of IL-1 and TNF- are all dependent of
F-B activity, and, because nuclear factors can be inhibited by
EVS sesquiterpene lactones, the extract’s ability to protect against
yperproliferative disorder is well explained. In addition, some
tudies have demonstrated that a reduction in the inﬂammation
y the multidose-TPA test can only be produced by corticoids and
OX inhibitors (Cuéllar et al., 2001).
Increased levels of leucotrienes were detected in inﬂamma-
ory and hyperproliferative skin diseases; therefore, inhibitors of
-lipoxygenase display beneﬁcial effects in inﬂammatory skin dis-
rders (Gábor, 2000). Moreover, an inhibition of the AA-induced
edema is connected with a reduction in LOX activity. This ﬁnding
s in agreement with the results obtained with the EEVS in the AA-
nduced oedema in which EEVS prevents ear oedema formation.
he AA and TPA-induced ear oedema models may  be useful for the
etection of the in vivo activity of COX/LOX inhibitors (Gábor, 2000).
ther studies have been shown that some antioxidants, histamine
nd serotonin antagonists also inhibit the AA-induced inﬂamma-
ion (Sanchez and Moreno, 1999).
Another model utilised in this work was  the repeated
pplication of the hapten oxazolone, which induces a contact-
elayed-type hypersensitivity (DTH) resembling human allergic
ontact dermatitis and characterised by a sustained ear swelling
nd marked polymorphonuclear and T lymphocytes inﬁltration
Fujii et al., 2002). Some cytokines (IL-2, TNF- and IFN) released
y activated T lymphocytes in the elicitation phase promote the
ctivation of macrophages that trigger an acute inﬂammation
esponse by the release of TNF-, IL-1, chemokines, prostaglandin
nd leucotrienes (Homey et al., 2006). Based on our results, we
uggest that EEVS acts essentially as an anti-inﬂammatory agent
nd not as an immunosupressor, given that only the elicitation
hase was responsive to the EEVS treatment in the DTH model.
he anti-inﬂammatory effect of EEVS in this model might be a con-
equence of the suppression of important inﬂammatory mediators,
uch as arachidonic acid metabolites involved in the inﬂammatory
esponse triggered after the elicitation phase.
Based on our results, we suggest that EEVS is effective against
cute and chronic skin inﬂammatory processes as well as delayed
ypersensitivity reaction and keratinocytes hyperproliferative dis-
rder. Moreover, the probable mechanism of action through which
EVS exerts its effects could involve several targets, resulting in
he reduction of important inﬂammatory mediators in the cuta-
eous tissue. Investigations into the mechanism of action of the
nti-inﬂammatory activity and into the compounds responsible for
he activity of EEVS are currently in progress.cknowledgments
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